

Issued by Citigate Dewe Rogerson Ltd, Birmingham
Date: Tuesday, 4 September 2007

IMMEDIATE RELEASE

Dechra[®] Pharmaceuticals PLC
An International Veterinary Pharmaceutical Business
Vetoryl[®] US – Development Update

Dechra Pharmaceuticals PLC ("*Dechra*") is pleased to announce that the USA Food and Drug Administration ("FDA") has granted *Vetoryl* Capsules a designation for a minor use in a major species ("MUMS") to treat hyperadrenocorticism due to adrenocortical tumours in dogs, which account for approximately 15% of Cushing's cases. This is the first such designation granted in the USA.

The benefit of a MUMS designation is that conditional approval for this minor indication can be received prior to the submission of the efficacy section for the full marketing authorisation. *Dechra* has also been notified that the FDA considers the safety section to be approved.

As indicated in the Preliminary Results statement released today (4 September 2007), the chemistry and manufacturing controls section ("CMC") has been submitted to the FDA for review. Marketing under the MUMS designation can commence once the CMC section is approved. Therefore, it is likely that *Dechra* will be able to launch the product for this minor indication ahead of management expectations. The application for the full marketing authorisation continues on schedule.

Enquiries:

Ian Page, Chief Executive
Simon Evans, Group Finance Director
Dechra Pharmaceuticals PLC
Today: 0207 638 9571
Mobile: 07775 642222 (IP) or 07775 642220 (SE)
Thereafter: 01782 771100

www.dechra.com
corporate.enquiries@dechra.com

Fiona Tooley, Director
Keith Gabriel, Senior Account Manager
Citigate Dewe Rogerson
Today: 0207 638 9571
Mobile: 07785 703523 (FMT) or 07770 788624
Thereafter: 0121 455 8370

Notes to Editors

Vetoryl Capsules is a novel and patented product for the treatment of Cushing's disease (excess cortisol or hyperadrenocorticism) in dogs. It is the only licensed product within the EU and is the only recognised safe and efficacious veterinary product for the treatment of Cushing's disease around the world. Launched in the UK on a provisional marketing authorisation in September 2001, *Vetoryl* Capsules has since achieved full approval and has consistently increased market penetration. It also achieved mutual recognition for approval within the EU in 2006 and has now been launched within all the key European territories. In the USA it is currently sold under an FDA waiver scheme.

Dechra and the *Dechra* 'D' logo are registered Trade Marks of *Dechra* Pharmaceuticals PLC and *Vetoryl* is a registered Trade Mark of the *Dechra* Group.